Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa lutetium-177 DOTATATE in children with relapsed or refractory high-risk neuroblastoma
2012-000510-10Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Oct 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in neuroblastoma, sponsored by University of Birmingham. Primary endpoint: Response rate at 1 month. Started Oct 2012; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2012-000510-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000510-10.